Previous 10 | Next 10 |
2024-01-11 08:15:15 ET More on Acorda Therapeutics Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript Acorda Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Acorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72M Financial ...
2024-01-11 05:46:14 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) have filed a marketing authorization application for their breakthrough Alzheimer's therapy, called Leqembi (lecanemab), in the EU. The application to the European Medicines Agency ...
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China TOKYO and CAMBRIDGE, Mass., Jan 10, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclona...
2024-01-09 05:30:25 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) announced on Tuesday market approval for their breakthrough Alzheimer's therapy, called Leqembi, in China. Leqembi (lecanemab), a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
2024-01-08 16:48:08 ET Biogen Inc. (BIIB) J.P. Morgan 42nd Annual Healthcare Conference January 08, 2024 02:15 PM EST Company Participants Chris Viehbacher - CEO Conference Call Participants Chris Schott - J.P. Morgan Presentation Chris Schott ...
2024-01-05 09:07:57 ET More on Big Pharma Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bri...
2024-01-05 10:17:57 ET More on Big Pharma Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bri...
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
2024-01-04 11:08:37 ET More on Ginkgo Bioworks Holdings Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty Ginkgo Bioworks: A Long Way To Go Ginkgo Bioworks: More Revenue Issues Gingko Bioworks, Synplogen to advance gene therapy services in Japan ...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...